Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fresenius Kabi Bidiphar is a joint venture between the German healthcare leader Fresenius Kabi and the Vietnamese pharmaceutical company Bidiphar. The company specializes in the manufacturing and distribution of infusion solutions, clinical nutrition, and intravenous generic drugs tailored for hospital care. Operating out of a WHO-GMP certified facility in Quy Nhon, Vietnam, it serves as a critical supplier for the national healthcare system and the Southeast Asian market. Its product portfolio includes essential medicines for fluid replacement, parenteral nutrition, and the treatment of serious infections. The partnership leverages Fresenius Kabi's global expertise in clinical nutrition and infusion therapy alongside Bidiphar's established local presence.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fresenius Kabi Bidiphar.